Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

GlobeNewswire October 5, 2020

Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

GlobeNewswire August 6, 2020

Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA

GlobeNewswire August 6, 2020

Y-mAbs to Announce Second Quarter 2020 Financial and Operating Results on August 6, 2020

GlobeNewswire August 4, 2020

Y-mAbs Announces Data to be Presented at 2020 SIOP

GlobeNewswire July 27, 2020

Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct

GlobeNewswire July 14, 2020

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

GlobeNewswire June 30, 2020

Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza(TM) (naxitamab) for the Treatment of Neuroblastoma for Priority Review

GlobeNewswire June 2, 2020

Y-mAbs Announces Data to be Presented at 2020 ASCO Annual Meeting

GlobeNewswire May 13, 2020

Y-mAbs Announces First Quarter 2020 Financial Results and Recent Corporate Developments

GlobeNewswire May 7, 2020

UPDATE - Y-mAbs to Announce First Quarter 2020 Financial and Operating Results on May 7, 2020

GlobeNewswire April 30, 2020

Y-mAbs to Announce 2019 Financial and Operating Results on May 7, 2020

GlobeNewswire April 30, 2020

Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors

GlobeNewswire April 24, 2020

Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology - a Novel Radioimmunotherapy Platform

GlobeNewswire April 15, 2020

Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

GlobeNewswire April 1, 2020

Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments

GlobeNewswire March 12, 2020

Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020

GlobeNewswire March 5, 2020

Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

GlobeNewswire February 26, 2020

Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2020

Y-mAbs' GD2-GD3 Vaccine Granted Rare Pediatric Disease Designation

GlobeNewswire December 12, 2019